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Background: Although Muscle Invasive Bladder Cancer (MIBC) is increasing in incidence, treatment has largely
remained limited to radical cystectomy with or without cisplatin-based neoadjuvant and/or adjuvant chemotherapy.
We reviewed the current and recent clinical trials evaluating perioperative chemotherapy, targeted therapy, and
novel therapeutic regimens for MIBC patients undergoing radical cystectomy.
Methods: An overview of perioperative MIBC management was conducted initially using MEDLINE. The Clinical
Trials Registry and MEDLINE were further searched specifically for perioperative MIBC chemotherapy, targeted
therapy, and other novel therapeutic approaches. Trials involving non-perioperative management, operative
management other than radical cystectomy, multiple tumors, or purely superficial or metastatic disease were
excluded from selection. These criteria were not specifically fulfilled for mTOR inhibitor and immune therapy trials.
Only phase III chemotherapy and phase II targeted therapy trials found in the Clinical Trials Registry were selected.
MEDLINE searches of specific treatments were limited to January 2009 to January 2014 whereas the Clinical Trials
Registry search had no timeline. Systematic MEDLINE searches had no phase restrictions. Trials known by the
authors to fulfill search criteria but were not found via searches were also selected.
Results: Twenty-five trials were selected from the Clinical Trials Registry including 7 phase III chemotherapy trials,
11 Phase II targeted therapy trials, 3 immune therapy trials, 1 mammalian target of rapamycin (mTOR) inhibitor trial,
and 3 gene and vaccine therapy trials. Nine trials have been completed and 5 have been terminated early or
withdrawn. Nine trials have data available when individually searched using MEDLINE and/or Google. Systematic
searches of MEDLINE separately found 12 trials in the past 5 years. Two phase III chemotherapy trials were selected
based on knowledge by the authors. No phase III trials of targeted therapy have been registered or published.
Conclusions: New trials are currently being conducted that may revolutionize MIBC treatment preceding or
following cystectomy. Head-to-head phase III trials of perioperative chemotherapy and further phase II and
phase III trials of targeted therapy and other therapeutic approaches are necessary before the current cisplatin-based
perioperative chemotherapy paradigm is altered.
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Bladder cancer is the 4th most common cancer in men
and 11th most common cancer in women in the United
States [1]. In total, 74, 690 new cases are diagnosed each
year with 15, 580 deaths annually [1]. Though rarer
worldwide compared to other cancers, bladder cancer is
also increasing in incidence globally as the use of tobacco
products becomes more prevalent in developing nations
[2]. In the United States, about 30% of these tumors
invade past both the bladder submucosa and mucosa and
are therefore defined as Muscle Invasive Bladder Cancer
(MIBC) [1].
Though MIBC is prevalent both in the United States
and internationally, treatment options for MIBC have
remained essentially unchanged for the past 25 years.
Traditionally, radical cystectomy has been the mainstay,
but as evidence accumulates for the benefit of periopera-
tive therapy, neoadjuvant or adjuvant cisplatin-based
chemotherapy have become more valid options for MIBC
patients [3-13]. Despite this success and that of other tri-
als, only 15-20% of patients will receive neoadjuvant
chemotherapy, though its prevalence has been increasing
over time [14]. The number of medical oncologists recom-
mending perioperative chemotherapy to their patients has
increased as almost 80% of 92 oncologists recently sur-
veyed have suggested perioperative chemotherapy to their
MIBC patients, albeit those physicians were well-versed in
bladder cancer treatment while many patients fail to have
access to such medical oncologists for socieoeconomic
reasons [15]. To continue the increasing trend of utilizing
perioperative chemotherapy, clinical studies should ad-
dress the overarching issues of predicting which patients
will more likely benefit from chemotherapy, identifying
particular chemotherapy regimens for specific patient
subsets, and developing more efficacious non-cisplatin
based regimens for patients who are cisplatin-ineligible. In
addition, there is a desperate need for continued explor-
ation of novel therapeutic treatment options to help
modernize the perioperative management of MIBC.
As of now, perioperative MIBC clinical research is mainly
focused on selecting a more efficacious cisplatin-based regi-
men using head-to-head trials with a limited number of
studies addressing regimens for cisplatin-ineligible patients.
Novel therapeutic approaches including targeted therapy,
mammalian target of rapamycin (mTOR) inhibitors, im-
mune therapy, and gene and vaccine therapy are now being
evaluated in early phase trials with cautious optimism.
Understanding the rationale and outcomes of these current
and recent trials is imperative for clinicians and investiga-
tors to continue to encourage patient participation in these
research efforts and to design future studies that enhance
our ability to offer personalized treatment for MIBC pa-
tients. The following is a systematic review of the current
and recent perioperative clinical trials conducted worldwidein the management of MIBC for patients undergoing
radical cystectomy with an evaluation of specific areas that
could benefit from future trials.
Methods
Data sources
Two separate databases were used to explore current and
recent clinical trials for the perioperative management of
MIBC. Initially, a Medical Literature Analysis and
Retrieval System Online (MEDLINE) search through
PubMed was completed for a general overview of the lit-
erature. This was followed by a search of all perioperative
trials for MIBC using the Clinical Trials Registry online
with the search phrase of “bladder cancer”. All trials se-
lected for further review from the Clinical Trials Registry
were independently searched using MEDLINE and Google
for published results. The initial overview of MEDLINE
abstracts and the Clinical Trials Registry search were used
to develop individual search equations based on the
different perioperative treatment classes for MIBC. Subse-
quently, MEDLINE was systematically searched for peri-
operative trials using these search equations. All search
equations for MEDLINE and the Clinical Trials Registry
are listed in Table 1. Lastly, any upcoming trials that are
currently unregistered with the Clinical Trials Registry but
were known by the authors to have been presented at any
major urology and/or oncology conference were included.
No new human subject data was studied requiring
approval from an institution’s ethics board.
Study selection
Trials involving non-perioperative management, periopera-
tive treatment for multiple tumors in addition to bladder
cancer, operative management other than radical cystec-
tomy, unconfirmed operative management, measured out-
comes solely of serum or urine biomarker concentration,
or purely metastatic or non-invasive disease were excluded
from selection. The exclusion criteria of “unconfirmed
operative management” was not strictly met for trials
obtained from the Clinical Trials Registry involving rapa-
mycin (mTOR) inhibition and immune therapy due to the
current limited number of trials in those fields.
Clinical trials of all phases were reviewed but only
current and recent phase III trials of perioperative chemo-
therapy and phase II trials of perioperative targeted
therapy found in the Clinical Trials Registry were selected
and further discussed. Trials of all phases from other peri-
operative treatment options were selected and evaluated.
Published MEDLINE clinical trials selected from the sys-
tematic review of each treatment class were limited to
data published between January 2009 and January 2014.
No phase restrictions were placed on these MEDLINE
systematic searches. Published MEDLINE trial data ob-
tained from independently searching individual trials
Table 1 Current and recent perioperative clinical trial systematic searches for MIBC*
Search category Database Search equation used Trials selected/reviewed
Broad overview of all
published abstracts
MEDLINE (“bladder cancer” OR “urothelial cancer” OR “urothelial cell carcinoma” OR
“transitional cell carcinoma”) AND (“bladder resection” OR “radical cystectomy”)
AND (“perioperative chemotherapy” OR “adjuvant chemotherapy” OR
“neoadjuvant chemotherapy” OR “targeted therapy” OR “biologic” OR
“immunotherapy” OR “gene” OR “vaccine” )
744 abstracts reviewed^
All registered clinical






MEDLINE ((neoadjuvant) AND (chemotherapy OR cisplatin OR gemcitabine OR carboplatin
OR methotrexate OR vinblastine OR doxorubicin OR adriamycin OR paclitaxel OR




MEDLINE ((adjuvant) AND (chemotherapy OR cisplatin OR gemcitabine OR carboplatin OR
methotrexate OR vinblastine OR doxorubicin OR adriamycin OR paclitaxel OR




MEDLINE (egfr inhibitor OR cetuximab OR erlotinib OR gefitinib OR genistein OR her-2
inhibitor OR lapatinib OR MGAH22 OR panitumumab OR trastuzumab) AND




MEDLINE (vegf inhibitor OR bevacizumab OR ramucirumab OR trebananib OR ziv
aflibercept) AND (bladder cancer OR radical cystectomy)
0/64
Trials of other Tyrosine
Kinase inhibitors
MEDLINE (tyrosine kinase inhibitor OR dasatinib OR pazopanib OR sorafenib OR sunitinib)




MEDLINE (mTOR inhibitor OR everolimus OR sirolimus OR temsirolimus OR rapamycin) AND




MEDLINE (Immune therapy OR interferon-alpha) AND (bladder cancer OR radical
cystectomy) AND (phase)
1/45
Trials of gene and
vaccine therapy
MEDLINE (vaccine OR gene therapy) AND (bladder cancer OR radical cystectomy)
AND (phase)
1/87
NIH = National Institute of Health.
MEDLINE =Medical Literature Analysis and Retrieval System Online.
*MEDLINE clinical trial abstracts were only reviewed dating from January 2009 to January 2014. Trials from the Clinical Trials Registry Online and the MEDLINE
broad overview of the literature had no date restrictions.
^No trials were individually selected from the MEDLINE broad overview of the literature. Treatment classes and specific drugs were taken from this MEDLINE
search and from the trials search of the Clinical Trials Registry to develop the systematic search equations for each individual treatment class.
#This result includes phase III perioperative chemotherapy trials, phase II targeted therapy trials, and clinical trials of all phases for mTOR inhibitors, immune
therapy, and gene and vaccine therapy.
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less of publication date.
Results
The current treatment paradigm for MIBC management
is conveyed in Figure 1. Outcomes from meta-analyses of
previous phase III perioperative chemotherapy trials are
reported in Table 2. The current and recent perioperative
clinical trials for MIBC are identified below based on drug
class. The classes include perioperative chemotherapy
(Table 3), targeted therapy (Table 4), mTOR inhibition
(Table 5), immune therapy (Table 5), gene therapy
(Table 6), and vaccine therapy (Table 6).
Perioperative chemotherapy trials
The initial MEDLINE review of 744 abstracts identified a
2005 meta-analysis for neoadjuvant chemotherapy of
phase III trials, an updated 2013 meta-analysis for adju-
vant chemotherapy of phase III trials, and a systematic re-
view of neoadjuvant and adjuvant chemotherapy trials
prior to September 2012 [17,19,34]. A 2004 neoadjuvantmeta-analysis by Winquist et al., the original 2005 adju-
vant meta-analysis by the Advanced Bladder Cancer
Meta-Analysis Corporation prior to the 2013 update, and
a 2013 neoadjuvant and adjuvant meta-analysis abstract
by Tjokrowidjaja et al. were also reviewed but were not
results of the original MEDLINE search [16,18,20]. The
results of the neoadjuvant and adjuvant meta-analyses are
described in Table 2. Individual current and recent phase
III neoadjuvant and adjuvant chemotherapy trials are de-
tailed in Table 3.
The Clinical Trials Registry search found a total of 12
neoadjuvant chemotherapy trials. These included 1
phase III trial, 10 phase II trials, and 1 phase 0 trial. The
1 phase III trial is a randomized control trial of high dose
methotrexate, viblastine, doxorubicin, and cisplatin MVAC
(HD-MVAC) compared to gemcitabine and cisplatin (GC)
at The University Hospital, Rouen. This study is also
accepting MIBC patients for adjuvant consideration. An
additional phase III trial investigated by The Southwest
Oncology Group has recently been registered involving a
comparison of dose dense MVAC (DD-MVAC) and GC,
Figure 1 Flow-chart of current management paradigm for patients with MIBC. RCT = Randomized Controlled Trial.
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Phase III trial has available results.
The systematic review of MEDLINE of neoadjuvant
chemotherapy identified 5 eligible trials out of 187 results.
Two of these publications referred to one single-arm study
of Gemcitabine with Carboplatin that resulted in safe, tol-
erable uptake of this regimen with a comparable efficacy
to cisplatin-based regimens [35,36]. Two other trials were
subset studies of previous large phase III trials and are not
described in Table 3 [37,38]. The review also identified a
phase II neoadjuvant erlotnib study that is discussed
further below as a targeted therapy [26]. Lastly, a recently
published phase III neoadjuvant MVAC trial by The JapanClinical Oncology Group, which was more recent than
our search timeline criteria, reported an improved overall
survival (OS) with the neoadjuvant arm but was not statis-
tically significant and is included in Table 3 [22].
A total of 9 adjuvant chemotherapy trials were found in
the Clinical Trials Registry. This included 6 adjuvant-only
phase III trials, 1 aforementioned neoadjuvant and adju-
vant trial from The University Hospital, Rouen, and 2
phase II trials. One of these 6 adjuvant-only phase III
trials, a National Cancer Institute trial of adjuvant MVAC
with gemcitabine compared to progression-triggered
MVAC with gemcitabine, was withdrawn prior to enroll-
ment. A Google and MEDLINE search for each of the
Table 2 Meta-analyses of perioperative chemotherapy phase III trials for MIBC
Study Treatment type Year Number of trials Patients Therapy OS (HR) DFS (HR)
Tjokrowidjaja et al. [16] Neoadjuvant +
Adjuvant
2013 21 3986 Only abstract available 0.86 0.77
(0.79 – 0.93) (0.71 – 0.84)
Tjokrowidjaja et al. [16] Neoadjuvant 2013 12 3047 Only abstract available 0.89 0.80
(0.81 – 0.98) (0.73 – 0.88)
Advanced bladder cancer-
Meta-analysis Corporation [17]
Neoadjuvant 2005 11 3005 Platinum-based 0.86 0.78
(0.77 – 0.95) (0.77 –0.95)
Winquist et al. [18] Neoadjuvant 2004 11^ 2605 Cisplatin-based 0.90 Insufficient data
for analysis+
(0.82 – 0.99)
Tjokrowidjaja et al. [16] Adjuvant 2013 9 939 Only abstract available 0.75 0.77
(0.63 – 0.90) (0.71 – 0.84)
Leow et al. [19] (Update of the
meta-analysis below)
Adjuvant 2013 9# 945 Cisplatin-based 0.77 0.66
(0.59 – 0.99) (0.45 – 0.91)
Advanced bladder cancer
meta-analysis corporation [20]
Adjuvant 2005 6* 491 Cisplatin-based 0.75 0.68
(0.60 – 0.96) (0.53 – 0.89)
OS: Overall Survival. DFS: Disease Free Survival. HR: Hazard Ratio.
^11 trials had HR data for OS and only 8 trials had HR data for DFS.
+Less than half the number of patients assessed were available for DFS results, and therefore, no statistical pooling analysis was undertaken.
#9 trials had HR data for OS and only 7 trials had HR data for DFS.
*6 trials had HR data for OS and only 5 trials had HR data for DFS.
Table 3 Current and recent perioperative chemotherapy phase III trials for MIBC
Institution Regimen Setting Status/Results Trial ID
University Hospital,
Rouen





DD-MVAC vs. GC Neoadjuvant Recruiting participants [21].
Japan Clinical Oncology
Group
MVAC vs. Immediate RC Neoadjuvant Completed. 130 total subjects. OS increased by
35% in MVAC arm (64 subjects) but was not
statistically significant. Improved pT0 rate
with MVAC [22].
FTRC GC vs. Immediate RC Adjuvant Completed. 192 total subjects. No difference
between adjuvant treatment (102) and control
arms for 5 year OS. Failed to reach accrual goal,
low study power [23].
NCT00054626
Cairo University GC + radiotherapy vs. radiotherapy
alone
Adjuvant Completed. 146 total subjects. Improvement in
45-month DFS from 28% to 70% in
chemoradiotheraphy (72) group but failed to




MVAC vs. PCa Adjuvant Completed. Results unreported. NCT00003701





Adjuvant Completed. 114 total subjects. No statistically
significant difference between adjuvant or
progression-triggered Gemcitabine for DFS
or OS. Failed to reach accrual goal [25].
NCT00146276
EORTC Adjuvant vs. Progression Triggered
MVAC + Gemcitabine
Adjuvant Closed early due to poor accrual NCT00028756
FTRC = Fondazione C.N.R./Regione Toscana “G. Monasterio”, Pisa, Italy. EORTC = European Organisation of Research and Treatment of Cancer. GC = Gemcitabine +
Cisplatin. MVAC =Methotrexate + Vinblastine + Doxorubicin + Cisplatin. RC = Radical Cystectomy. PCa = Paclitaxel + Carboplatin. HD = High Dose. DD = Dose Dense.
OS = Overall Survival. DFS = Disease Free Survival.
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Table 4 Current and recent perioperative targeted therapy phase II trials for MIBC
Institution Regimen Receptor target Setting Results/Status Trial ID
University of North
Carolina
Erlotinib EGFR Neoadjuvant Completed. Well tolerated. 35% (7/20)






MDACC Erlotinib EGFR Neoadjuvant Ongoing NCT00749892
Dendreon DN24-02 HER2R Adjuvant Ongoing. Updated results: 75% of 226
patients had HER2 expression in primary
tumor, 84% in lymph nodes. APC activation
for all 30 patients who have received








Ongoing. Preliminary results: 42% (5/12)
postoperative complication rate. 31%
(4/13) downstaging preoperatively [28].
NCT00268450
MDACC Bevacizumab +MVAC VEGFR-A Neoadjuvant Ongoing NCT00506155
FTRC Sorafenib + GC VEGFR + PDGFR* Neoadjuvant Unknown. NCT01222676
US Oncology Sunitinib + GC VEGFR + PDGFR* Neoadjuvant Terminated early due to patient toxicity.
Only 9 MIBC patients studied for
neoadjuvant therapy [29].
MSKCC Sunitinib + GC VEGFR + PDGFR* Neoadjuvant Completed early due to limited study
accrual. pT0 rate was low with combination [30].
NCT00847015
CCCC Sunitinib VEGFR + PDGFR* Neoadjuvant Completed, Results Unreported NCT00526656
Hoosier Oncology
Group
Dasatinib BCR/Abl^ Neoadjuvant Completed. Well tolerated. Follow-up
pathology study: SFK expression





Sunitinib VEGFR + PDGFR* Adjuvant Terminated due to poor accrual NCT01042795
Hoosier Oncology
Group
Sunitinib + GC VEGFR + PDGFR* Neoadjuvant Terminated due to patient toxicities NCT00859339
MDACC =M.D. Anderson Cancer Center. FTRC = Fondazione C.N.R./Regione Toscana “G. Monasterio”, Pisa, Italy. MSKCC =Memorial Sloan-Kettering Cancer Center.
CCCC = Case Comprehensive Cancer Center. GC = Gemcitabine and Cisplain. MVAC =Methotrexate, Vinblastine, Doxorubicin, Cisplatin. SFK = SRC Family Kinase.
APC: Antigen Presenting Cell.
*Sorafenib and Sunitinib target multiple receptor tyrosine kinases (RTKs) in addition to the aforementioned receptors.
^Dasatinib targets multiple tyrosine kinases.
#This trial includes neoadjuvant bevacizumab with GC followed by surgery and adjuvant bevacizumab and paclitaxel.
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Cognetti et al. at Fondazione C.N.R./Regione Toscana
evaluated adjuvant GC vs. cystectomy alone and found no
difference in OS, but the study failed to achieve its accrual
goal [23]. A phase III trial at The Cairo University byTable 5 Current mTOR inhibitor and immune therapy trials fo
Institution Regimen Setting Tr
UTHSCSA Sirolimus Neoadjuvant Ph
Tis
Hoosier oncology group Everolimus +/− Paclitaxel Unspecified^ Ph
No
University of Washington Sirolimus + GC Unspecified^ Ph
Pa
MDACC INF-alpha Prior to Biopsy Ph
tre
GC = Gemcitabine + Cisplatin. UTHSCSA = The University of Texas Health Science Ce
TURBT = Transurethral Resection of Bladder Tumor.
*Table does not include trials for multiple solid tumors that may include bladder ca
^Unspecified regimens can be given in the neoadjuvant, adjuvant, locally recurrentZaghloul et al. of GC with radiotherapy did show an
increase in disease free survival (DFS) but failed to reach
statistical significance [24]. The Association of Urogenital
Oncology’s phase III trial of adjuvant gemcitabine com-
pared to disease progression-triggered gemcitabine forr MIBC*
ial description Status Trial ID
ase 0 trial for preoperative treatment.
sue evaluated before and after treatment.
Recruiting NCT01827618
ase II trial for Cisplatin ineligible patients.
t a perioperative specific study.
Recruiting NCT01215136
ase I/II trial for disease of any stage.
tients likely will undergo cystectomy.
Ongoing NCT01938573
ase 1 trial with TURBT conducted following
atment. Radical cystectomy may follow.
Ongoing NCT00082719
nter at San Antonio. MDACC =M.D. Anderson Cancer Center.
ncer as a subset.
, or metastatic setting.
Table 6 Current and recent perioperative gene and vaccine therapy trials for MIBC*
Institution Therapy Trial description Status/Outcomes Trial ID
Uppsala University Gene Phase 1/IIa Intravesical instillation of
AdCD40L that may improve anti-tumor
immune response. Cystectomy followed
phase 1 trial.
Completed. 8 patients with limited
complications. Successful gene
transfer detected in biopsies [33].
NCT00891748
Celldex Therapeutics Vaccine Phase II neoadjuvant and adjuvant
administration of CDX-1307 vaccine
with chemotherapy for bladder tumors
expressing B-HCG protein for patients
undergoing radical cystectomy.
Terminated due to lack of enrollment. NCT01094496
MSKCC and NCI Vaccine Phase 1 adjuvant administration of NY-ESO-1
peptide vaccine with BCG + sargramostim for
tumors expressing NY-ESO-1 or LAGE-1
antigens. Patients previously underwent
radical cystectomy.
Competed. Results unreported. NCT00070070
*Table does not include trials for multiple solid tumors that may include bladder cancer as a subset.
MSKCC =Memorial Sloan-Kettering Cancer Center.
NCI = National Cancer Institute.
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cant outcomes [25].
The systematic review of MEDLINE of adjuvant chemo-
therapy identified 5 eligible studies out of 259 results. One
study is the aforementioned phase III trial conducted by
Cognetti et al. and is included in the 2013 updated meta-
analysis by Leow et al. [23]. One phase II trial showed
benefit using adjuvant GC or MVAC compared to obser-
vation alone following cystectomy [12]. Three selected tri-
als were neoadjuvant studies including 1 small single-arm
study evaluating the efficacy and tolerability of a split-
dosed cisplatin regimen for patients with renal impair-
ment that was not found with the neoadjuvant chemo-
therapy trials systematic review [37-39].
Perioperative targeted therapy trials
A total of 11 phase II targeted therapy trials were identi-
fied using the Clinical Trials Registry as detailed in Table 4.
No phase III trials met study eligibility criteria. Seven were
neoadjuvant trials, 2 were adjuvant trials, and 2 were both
neoadjuvant and adjuvant trials. Of these 11 trials, 1 adju-
vant trial of sunitinib by The University of Michigan was
terminated due to poor accrual and 1 neoadjuvant trial of
sunitinib with GC by The Hoosier Oncology Group was
terminated due to patient toxicities. Five trials included
combinations with chemotherapy with 1 trial being the
neoadjuvant sunitinib trial that was terminated. A Google
and MEDLINE search of each clinical trial found results
for 3 studies. Preliminary results of a neoadjuvant trial of
Bevacizumab and GC followed by adjuvant Bevacizumab
and Paclitaxel at The Medical University of South
Carolina have shown a high surgical complication rate
though further results are pending [28]. A neoadjuvant
trial of sunitinib and GC at Memorial-Sloan Kettering
Cancer Center failed to show a significant rate of pT0
disease at surgery [30]. A trial of neoadjuvant dastanib by
The Hoosier Oncology Group was well tolerated andfurther showed a marked decrease in tumor phosphory-
lated SRC Family Kinase (SFK) expression levels but failed
to show changes in cell proliferation [31,32].
The independent MEDLINE search of epidermal growth
factor receptor (EGFR) inhibitors found 1 eligible study
out of 89 results. This was a published phase II study in-
volving neoadjuvant erlotinib at the University of North
Carolina conveying erlotinib to be well-tolerated with a
substantial pre-surgical downstaging rate [26].
Our MEDLINE search of vascular epithelial growth factor
(VEGF) inhibitors provided 0 eligible trials out of 64 results.
Our search of other possible tyrosine kinase inhibitors
provided 1 eligible trial out of 106 results. This was a neoad-
juvant sunitinib with GC study published by US Oncology
that was terminated early due to patient toxicities [29].
Perioperative mTOR inhibitor trials
A total of 3 trials were selected from the Clinical Trials
Registry involving mTOR inhibitors. These trials included
a phase 0 neoadjuvant sirolimus trial by The University of
Texas Health Science Center at San Antonio, a phase II
everolimus with paclitaxel and carboplatin (PCa) trial by
The Hoosier Oncology Group, and a phase I/II sirolimus
with GC trial by The University of Washington. The phase
II trial by The Hoosier Oncology Group is not a periopera-
tive specific study. The phase I/II trial by The University of
Washington includes patients that are likely to undergo
cystectomy but will be further evaluated for surgery based
on clinical judgment. The University of Washington phase
I/II trial also involves non-invasive and metastatic disease.
Our MEDLINE search found 0 eligible trials out of 84
abstracts.
Perioperative immune therapy trials
One immune therapy trial was selected from the Clinical
Trials Registry as described in Table 5. This was a phase
I trial of interferon-alpha being administered prior to
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who are potential candidates for radical cystectomy at
The M.D. Anderson Cancer Center. The trial was not a
perioperative specific study.
The MEDLINE search found 1 eligible trial out of 45 ab-
stracts. This study was also found in the gene and vaccine
therapy systematic review and is further discussed below
and included in Table 6.
Perioperative gene and vaccine therapy trials
1 phase I/II gene therapy trial was found using the Clinical
Trials Registry. This was a completed study of the
AdCD40L vaccine by Uppsala University, which was also
found in the perioperative immune therapy MEDLINE
search. 1 phase I vaccine therapy trial and 1 phase II vac-
cine therapy trial were found on the Clinical Trials Registry.
The phase 1 trial sponsored by Memorial Sloan Kettering
Cancer Center and The National Cancer Institute involving
the adjuvant administration of NY-ESO-1 following radical
cystectomy has been completed but the results remain
unreported. The phase II trial sponsored by Celldex Thera-
peutics involving the neoadjuvant administration of a
vaccine for beta-Human Chorionic Gonadotropin (bHCG)
expressing MIBC tumors was terminated due to a lack of
enrollment. The gene therapy and vaccine therapy trials are
detailed in Table 6.
Our MEDLINE search for both gene therapy and vaccine
therapy found 1 eligible trial out of 87 results. This was the
published results of the AdCD40L immunogene adminis-
tered as intravesical therapy prior to cystectomy conveying
tolerable uptake of the treatment [20].
Discussion
Thus far, the perioperative medical management of MIBC
has largely been limited to platinum-based chemotherapy
regimens, particularly involving cisplatin as described in
Figure 1. Our systematic review identifies the current
clinical trials evaluating perioperative chemotherapy
regimens, targeted therapy, and other novel treatment
options. Below, we address the benefits and limitations of
these trials as well as highlight the need for further
particular studies.
Neoadjuvant chemotherapy trials
Though neoadjuvant chemotherapy has been proven
beneficial, further research is necessary towards selecting
a particular regimen based on patient demographics and
tumor specifics particularly for patients who are cisplatin-
ineligible. The 2005 meta-analysis conducted by The
Advanced Bladder Cancer Meta-Analysis Collaboration
found a 14% risk reduction in mortality or a 5% increase
in 5-year OS with the use of neoadjuvant chemotherapy
prior to radical cystectomy [17]. Over 90% of patients re-
ceived cisplatin-based regimens [17]. Clinicians oftensubstitute regularly-dosed cisplatin for split-dosed cis-
platin or carboplatin for patients with medical comorbidi-
ties, mainly renal impairment. On the contrary, both the
European Association of Urology (EAU) and The Society
of Urologic Oncology recommend proceeding directly to
radical cystectomy if patients cannot tolerate cisplatin-
based treatment [40,41]. Winquist et al. similarly found a
10% risk reduction in a 2004 meta-analysis of 11 trials
with a 13% risk reduction or a 6.5% increase in OS in the
8 trials for patients undergoing a combination chemother-
apy regimen [18]. All trials were cisplatin-based [18].
Lastly, Tjokrowidjaja et al. found a 11% risk reduction in
the most recent 2013 meta-analysis, though only the ab-
stract data is available and details of the patient population
and 12 trials used have yet to be published [16]. Interest-
ingly, no direct comparisons between neoadjuvant chemo-
therapy regimens have been completed in a phase III trial.
Our review identified 2 new phase III trials including
HD-MVAC compared to GC at The University Hospital,
Rouen and DD-MVAC compared to GC by The Southwest
Oncology Group and 1 recently published phase III trial of
MVAC by The Japan Clinical Oncology. The University
Hospital, Rouen trial is both a neoadjuvant and adjuvant
study with a goal of 500 total patients. The Southwest
Oncology Group study is referred to as the Co-expression
Extrapolation (CoXEN) trial because tumor messenger
RNA, DNA, and stem cell biomarkers will be evaluated
prior to administering MVAC or GC [21]. Choi et al. of
The Southwest Oncology Group has previously shown that
MIBC with protein properties to that of p53-mutated
breast cancers have increased chemoresistance to cisplatin
[42]. Additionally, other genomic characteristics of MIBC
may help clinicians select an appropriate chemotherapy
regimen. Therefore, the CoXEN trial can offer information
as to which patients may benefit from chemotherapy and
whether MVAC or GC is more appropriate based on
tumor genetics. Overall, both The University Hospital,
Rouen and The Southwest Oncology Group trials will offer
insight into the safety profiles and efficacy of the two
regimens when directly compared in a prospective
randomized fashion. Neither of these trials compares
chemotherapy regimens to a control group of cystec-
tomy without neoadjuvant treatment. Lastly, Kitamura
et al. of The Japanese Clinical Oncology Group found a
35% increase in OS for patients undergoing neoadju-
vant MVAC compared to cystectomy-alone but did not
quite reach statistical significance (p = 0.07) [22]. This
study was closed early due to poor accrual and had a
total of 64 patients in the neoadjuvant arm and 66
patients in the radical cystectomy-only arm [22].
Though the results were not statistically significant, this
recently published trial offers continued cautious sup-
port for a cisplatin-based regimen in the neoadjuvant
setting.
Vashistha et al. BMC Cancer 2014, 14:966 Page 9 of 15
http://www.biomedcentral.com/1471-2407/14/966Addressing the role of neoadjuvant chemotherapy for
cisplatin-ineligible patients has been difficult. Only 1
phase III neoadjuvant trial from 1997 has been conducted
for carboplatin-based treatment [43]. Our MEDLINE re-
view of neoadjuvant chemotherapy identified a single arm
prospective trial of gemcitabine and carboplatin leading to
a 24.1% (28/116) pT0 stage at surgery and an 89.7% OS
rate with a median follow-up of 41 months [35,36]. 44% of
these patients were ruled cisplatin-ineligible [35,36]. The
study was hampered by a single arm design at a single in-
stitution with a shortened follow-up timeframe [35,36].
Moreover, phase II carboplatin-based regimen trials have
showed either no change in efficacy or worse efficacy than
cisplatin-based regimens with varying levels of toxicity
[44,45]. Furthermore, our adjuvant chemotherapy MED-
LINE review identified a phase II neoadjuvant split-dosed
cisplatin study for MIBC patients [39]. The treatment
regimen was well-tolerated with 11 of 23 patients achiev-
ing complete response to neoadjuvant treatment while 0
out of the 10 patients with chronic kidney disease had fur-
ther decline in renal function [39]. The study was limited
as only 6 patients underwent radical cystectomy while
others preferred organ-sparing or palliative treatment due
to age or comorbidities, but nevertheless, the split-dosed
cisplatin regimen offers a possible alternative to traditional
cisplatin-based therapy for patients who have renal im-
pairment [39]. To our knowledge, no phase III split-dosed
cisplatin trials have been conducted, thus reaffirming The
EAU and The Society of Urologic Oncology’s stance for
preceding directly to cystectomy for cisplatin-ineligible
patients [40,41].
The role of future trials in neoadjuvant chemotherapy
should continue to assess particular regimens based on
individual patient demographics and tumor specifics.
Randomized, multi-center phase III trials for split-dosed
cisplatin and carboplatin are also needed for possible
evidence-based alternatives for patients who are unable
to tolerate a traditional cisplatin-based regimen. Though
meta-analysis data has proven its efficacy, several ques-
tions still need to be investigated to improve the benefit
of neoadjuvant chemotherapy on a personalized level.
Adjuvant chemotherapy trials
Adjuvant chemotherapy for MIBC has recently been
shown to be beneficial though a specific regimen based on
patient characteristics has yet to be discerned. The
updated 2013 meta-analysis by Leow et al. reported a 23%
risk reduction in mortality with adjuvant chemotherapy
[19]. All trials involved cisplatin-based regimens [19]. In
total, only 945 patients were used in the meta-analysis
compared to the 3005 patients and 3047 patients included
in the most recent neoadjuvant chemotherapy meta-
analyses [16,17,19]. Additionally, the results suggest that
adjuvant chemotherapy may play a greater role in patientswith lymph node positive (N+) disease [19]. The 2013 up-
date by Leow et al. added 3 trials and updated 1 trial to
the original 6 trials included in the 2005 meta-analysis by
the Advanced Bladder Cancer Meta-Analysis Corporation
[19,20]. The original meta-analysis was limited by a low
study power with only 491 patients included [20]. In a
separate analysis, Tjokrowidjaja et al. reported a 25% risk
reduction in mortality with 939 patients, which is consist-
ent with the findings of Leow et al. [16,20] The limited
number of patients in all meta-analyses leads to difficulty
towards recommending adjuvant therapy to all MIBC pa-
tients post-cystectomy. In fact, The EAU has yet to recom-
mend adjuvant chemotherapy [40]. Recent commentary
on the EAU guidelines by Sternberg et al. as well as the
perioperative chemotherapy summary from The 2012
Society of Urologic Oncology Annual Meeting suggest
that this is purely because the data on adjuvant chemo-
therapy is insufficient [45,46].
Our review identified 6 phase III trials registered with
the Clinical Trials Registry including 1 completed head-to-
head trial, 3 trials involving GC, and 2 comparing a
traditional adjuvant delivery with a disease progression-
triggered schedule. The head-to-head trial is a comparison
of MVAC with PCa completed by The Eastern Cooperative
Oncology Group though the results have yet to be
reported. To our knowledge, this is the first completed
periopertive chemotherapy trial directly comparing two
chemotherapy regimens. This trial can offer insight into
taxane-based regimens compared to traditional cisplatin-
based treatments. PCa has been studied in the past as a
single-arm trial of 92 patients showing tolerable patient
uptake with a 5-year OS of 28.9% [47]. A head-to-head
comparison with a traditional regimen will shed light on
the efficacy of a taxane-based regimen and may prove its
value for cisplatin-ineligible patients.
Three of the adjuvant trials selected by our review
involve the use of GC alone, GC with radiotherapy, or GC
delivered via the intrarterial route. Cognetti et al. of
Fondazione C.N.R./Regione Toscana evaluated adjuvant
GC at tumor relapse compared to cystectomy alone and
found a 5-year OS hazard ratio (HR) of 1.29 in the
treatment arm but failed to reach statistical significance
(p = 0.24) [23]. Only 194 patients were included and the
study failed to reach its accrual goal forcing the study to
be closed early [23]. This study is included in the 2013
meta-analysis by Leow et al., and to our knowledge, is the
first completed adjuvant phase III trial of GC alone, which
is a common regimen for neoadjuvant therapy [19]. An-
other phase III trial at The Cairo University by Zaghloul
et al. compared adjuvant GC with radiotherapy with
postoperative radiotherapy alone and showed an increase
in 45-month DFS from 28 +/− 20% to 70 +/− 6% in the
chemotherapy arm but failed to be statistically significant
(p = 0.18) [24]. Chemoradiation has been proven effective
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pooled-analysis of phase II and phase III trials, but this
publication by Zaghloul et al. is the first phase III trial
evaluating chemoradiation in the post-cystectomy setting
[48]. Though the findings were not statistically significant,
the combination of adjuvant GC with radiotherapy im-
proved DFS, which suggests that adjuvant chemoradiation
should be studied more extensively in the future [24].
Lastly, a current phase III study by Sun Yat-Sun University
is evaluating the use of 1–3 cycles of intrarterial GC for
adjuvant use within 1–5 weeks following cystectomy.
Previously, a retrospective trial comparing 25 patients
receving intraarterial GC with 35 patients solely undergo-
ing cystectomy has recently been published by Jiang et al.
[49] The data from the retrospective study is promising as
the HR for 1-year survival dropped to 0.18 (p = 0.04) in
the adjuvant treatment arm with the most common adverse
effect being transient myelosuppresion (40%) [49]. A phase
III trial of such a delivery method will shed better insight
into the intraarterial options for adjuvant chemotherapy.
The last two adjuvant chemotherapy trials identified by
our review investigate the role of disease progression-
triggered delivery of adjuvant chemotherapy compared to
a traditional adjuvant delivery. The Association of Uro-
genital Oncology phase III trial of adjuvant gemcitabine
compared to disease progression-triggered gemcitabine
for cisplatin-ineligible patients showed an increase in DFS
(HR 1.375), cancer specific survival (HR 1.166), and 3-year
OS (HR 1.225), but failed to show statistical significance
for any of these outcomes (p = 0.335, p = 0.622, p = 0.426,
respectively) [25]. Of note, the trial closed early and in-
cluded 114 patients for analysis rather than the planned
178 patients [25]. Nonetheless, the trial offered an alterna-
tive to cisplatin-based treatment with a novel delivery
time. Lastly, the Eastern Organisation for Research and
Treatment of Cancer phase III trial of adjuvant MVAC vs.
disease progression-triggered MVAC was withdrawn prior
to enrollment. Currently, evidence fails to suggest that a
non-cisplatin based regimen or a progression-triggered
treatment is beneficial in the adjuvant setting.
Neoadjuvant chemotherapy has thus far been more
thoroughly studied than adjuvant chemotherapy as
highlighted by the larger number of patients included in
the neoadjuvant meta-analyses. Regardless, similar to the
current need in neoadjuvant chemotherapy clinical re-
search for MIBC, more head-to-head phase III adjuvant
chemotherapy trials are necessary to understand the
benefits and drawbacks of particular regimens with the
hopes of offering a certain combination based on patient
and tumor specifics. Additionally, further trials particu-
larly studying N+ patients can offer insight into the
benefit of adjuvant chemotherapy. One previous phase II
trial conveyed that GC is a tolerable adjuvant regimen
for N+ disease while a phase III trial included in theupdated 2013 meta-analysis by Leow et al. concluded
that a cisplatin-based adjuvant regimen can particularly
benefit patients with > pT3 and/or N+ disease [19,50,51].
Focusing phase III trials on this particular group of pa-
tients may define a specific role for adjuvant chemother-
apy. Finally, current shortcomings of adjuvant trials are
likely due to poor accrual forcing studies to close early.
Clinicians and investigators need to continue to encour-
age patients to participate in these trials to improve our
understanding of adjuvant chemotherapy.
Perioperative targeted therapy trials
Thus far, the role of targeted therapy in the perioperative
management of MIBC is convoluted because of the lim-
ited data from clinical studies. No active phase III trials of
perioperative targeted therapy were identified by our sys-
tematic review. Our review identified 11 currently active
or recently completed phase II trials. Eight of these studies
are purely neoadjuvant with 2 other trials evaluating a
combination of neoadjuvant and adjuvant therapy. This
discrepancy between the number of neoadjuvant and
advjuvant targeted therapy trials may be attributed to neo-
adjuvant chemotherapy being considered beneficial for a
much longer time and with larger phase III studies than
adjuvant chemotherapy. Five trials include targeted ther-
apy combination treatment with chemotherapy. For 4 of
these trials, the chemotherapy selected for combination
treatment include traditional cisplatin-based regimens,
which is expected as cisplatin-based regimens dominate
the options for perioperative chemotherapy for MIBC. Of
note, the Dendreon adjuvant study of DN24-02, which is
designed to stimulate an immune response against the
human epidermal growth factor receptor 2 (HER2) is
discussed below as an immune therapy.
Erlotinib may be considered the best candidate for a fu-
ture phase III trial of targeted therapy. Unlike other tar-
geted therapies, erlotinib is mainly being evaluated alone
without combination chemotherapy. A phase II trial of
neoadjuvant erlotinib with 20 clinical T2 patients at The
University of North Carolina led to 7 (35%) patients being
downstaged to < pT1 at cystectomy without significant tox-
icity [26]. Since this trial was not a combination treatment
trial with chemotherapy, the results convey that erlotinib
alone can possibly offer neoadjuvant intervention. Two ac-
tive erlotinib trials are currently being investigated by The
University of North Carolina and M.D. Anderson Cancer
Center, which will further offer insight on the safety and ef-
ficacy of erlotinib alone for neoadjuvant MIBC.
Multiple phase II trials of bevacizumab with chemother-
apy are assessing the role of the VEGF inhibitor in peri-
operative MIBC management. A phase II trial by The
Medical University of South Carolina evaluating bevacizu-
mab with GC in the neoadjuvant setting and bevacizumab
with paclitaxel in the adjuvant setting reported a 31%
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rate for 13 patients in 2011 [28]. All patients underwent
neoadjuvant therapy but only 2 patients underwent adju-
vant treatment, and therefore, the effect of paclitaxel with
bevacizumab cannot yet be predicted [28]. Postoperative
complications included enterovesical fistula, ileus, and pel-
vic abscess [28]. Further patient accrual for the study will
help describe whether the downstaging rate will be benefi-
cial enough to use bevacizumab despite its high surgical
complication risk once more results are reported. In
addition, bevacizumab is currently being evaluated with
MVAC by M.D. Anderson Cancer Center, which will
further offer outcomes of the added treatment. Further
information is needed currently for bevacizumab before a
phase III trial can be undertaken.
Five of our 12 reviewed phase II targeted therapy trials
involve sunitinib, but 2 of these studies by The University
of Michigan and The Hoosier Oncology Group have been
withdrawn due to poor accrual or patient toxicities,
respectively. A trial of sunitinib with GC by US Oncology
was also terminated early due to a hematologic toxicity
rate of 70% despite lower dosing of GC to offset early ad-
verse effects [29]. Only 9 MIBC cases were evaluated prior
to radical cystectomy, but 22% (2/9) patients did have
complete pathologic response to treatment [18]. The same
regimen was studied at Memorial Sloan-Kettering Cancer
Center and was hampered by a low pT0 rate of 31%
(4/13), which is a slightly decreased rate to that of GC or
MVAC neoadjuvant therapy alone, thus suggesting a lim-
ited efficacy of the added sunitinib [4,30,52]. Case Com-
prehensive Cancer Center has recently completed a trial
of neoadjuvant sunitinib alone, which will hopefully assess
whether sunitinib can have a role monotherapy, but the
results remain unreported. Neoadjuvant sunitinib has not
been proven beneficial at this time either as a monother-
apy or as a combination therapy and evidence does not
currently warrant a phase III trial.
Our review also identified 2 trials involving dasatinib and
sorafenib as possible perioperative targeted therapies. A
phase II trial of dasatanib monotherapy by The Hoosier
Oncology Group of 25 patients was tolerated by 68% with
4% undergoing hematologic toxicity [31]. The follow-up
pathology results conveyed a decrease in phosphorylated
SFK expression in 77% (14/18) of patients but failed to
show a change in cell proliferation or apoptosis while not
identifying a downstaging rate [32]. Phosphorylated
SFK expression is a common and specific histologic
manifestation of bladder cancer [32]. Further investiga-
tion is required to understand how dastanib’s effect on
phosphorylated SFK expression can alter patient out-
comes and if this actually has any clinical role towards
treating MIBC. Lastly, our review found a sorafenib
with GC study at Fondazione C.N.R./Regione Toscana,
though the status of this study remains unreported.The next step towards considering targeted therapy as
a legitimate option for the perioperative management of
MIBC would be a phase III trial. The most feasible op-
tion would be to await the results of the 2 current erloti-
nib clinical trials at The University of North Carolina
and The M.D. Anderson Cancer Center. Based on the
findings from these studies in addition to the published
results from a previous University of North Carolina
neoadjuvant erlotinib trial, erlotinib alone could be a
candidate for a phase III trial [26]. Further phase II trials
of neoadjuvant dasatinib addressing tumor staging fol-
lowing treatment could lead to a phase III trial. As of
now, an appropriate regimen for a phase III trial of
chemotherapy and targeted therapy would be difficult to
elucidate based on the current data.Perioperative mTOR inhibitor trials
The mTOR protein serves as a regulator for cell growth
and proliferation based on stimuli stemming from nutri-
ent availability and energy processes within the cell [53].
The upregulation of this protein has been shown in solid
tumors and hematologic malignancies, and therefore, in-
hibition of the mTOR protein can limit malignancy
growth for patients refractory to other treatments [53].
Consequently, the role of mTOR inhibitors is now being
evaluated in bladder cancer. Everolimus has been shown
to affect bladder cancer lines in vitro and in mouse
models [54]. Additionally everolimus has been combined
with cisplatin to decrease cell proliferation in vitro [55].
Temsirolimus and Everolimus have been studied as
phase II trials in metastatic urothelial cancer [56,57].
However, no perioperative specific trials for MIBC have
been completed.
Our review identified 1 phase 0 neoadjuvant trial of sir-
olimus at The University of Texas Health Science Center
at San Antonio. This trial is of particular importance be-
cause it can offer evidence that mTOR inhibitors can be
safely tolerated in patients undergoing a major cystectomy
operation. Additionally, despite failing to fulfill criteria as
being perioperative specific studies, we selected an
everolimus with paclitaxel trial by The Hoosier Oncology
Group and a sirolimus with GC trial by The University of
Washington. These trials were selected because of the lack
of current available mTOR inhibitor trials. The everolimus
with paclitaxel phase II trial is a first-line therapy for inva-
sive bladder cancer for patients who are not candidates for
cisplatin-based treatment. The sirolimus with GC trial is a
phase I/II study for patients who are likely to undergo
cystectomy, thus it can be considered a neoadjuvant study,
but surgical intervention is not definitive based on the
Clinical Trials Registry information. The results from
these studies may promote pure perioperative studies of
mTOR inhibitors in the future.
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mTOR inhibitors for MIBC are imperative to encourage
their use. As of now, no real clinical data can define the
role of mTOR inhibitors for MIBC patients undergoing
cystectomy.
Perioperative immune therapy trials
Immune therapy has yet to be thoroughly studied in blad-
der cancer. A large phase II trial has been previously con-
ducted evaluating interferon-alpha 2B with The Bacillus
Calmette–Guérin (BCG) vaccine in non-invasive bladder
cancer [58]. Interferon-alpha-2B has further been studied
independently for non-invasive bladder cancer as intrave-
sical administration for patients who failed BCG therapy
[27]. However, no trials have been completed examining
immune therapy for MIBC.
Despite not fulfilling criteria for being a perioperative
specific study, we selected a trial of interferon-alpha for
advanced bladder cancer at M.D. Anderson Cancer Center.
Evaluating the tolerability of interferon-alpha in advanced
bladder cancer can help define the safety profile of the
treatment. The trial was selected due to the scarcity of im-
mune therapy trials for MIBC. In addition, an ongoing trial
reported in Table 4 by Dendreon of DN24-02, an immune
stimulant against HER2, includes the use of culturing per-
ipheral blood mononuclear cells with recombinant antigen
BA7072 following 3 2-week cycles of leukopharesis and in-
fuses this product back into the patient’s bloodstream [59].
BA7072 is a fusion protein of HER500, a protein that has
intracellular and extracellular elements of HER2, and
granulocyte-macrophage colony-stimulating factor, which
enhances activation of antigen presenting cells (APC’s).
Measured responses of the trial include serum APC activa-
tion, particularly BA7072 and HER500 specific antibody
proliferations [59]. Thus far, 226 patients have been en-
rolled in this trial with 75% of these patients having some
level of HER2 expression in the primary tumor and 84% in
lymph node samples. Thirty patients have undergone the
full 3 infusion cycles with APC activation evident after
each infusion but responses were greater at infusions 2 and
3 than at infusion 1 [59]. Further long-term results can
describe the actual effect of DN24-02 on clinical outcomes.
On an overarching note, the administration of DN24-02
can be considered a mixture of targeted therapy with im-
mune therapy considerations. Given the heterogeneity of
bladder cancer biology, and the clear need for less toxic,
non-cisplatin based therapies and therapies for patients in
whom neoadjuvant chemotherapy has failed, the fact that
this phase II trial actually met its accrual goal should be
celebrated as enthusiasm for rational targeted therapy by
investigators for MIBC.
Moving forward, perioperative specific trials of
interferon-alpha and a further phase III trial of DN24-02
are necessary to understand their efficacy and tolerabilityamong patients undergoing cystectomy. The data for im-
mune therapy is currently too limited to suggest its benefit
in MIBC.
Perioperative gene and vaccine therapy trials
Gene and vaccine therapy trials for MIBC are being evalu-
ated for patient tolerability. A phase I/IIa trial of AdCD40L
by Uppsala University used an intravesical administration
of an adenovirus vector to upregulate the human CD40 lig-
and in MIBC patients scheduled for cystectomy [33]. Only
1 out of 8 patients experienced a serious adverse effect
postoperatively, and the histologic samples showed in-
creased immune activation and decreased cell proliferation
with successful gene transfer [33]. Though only an early
phase trial, the study conveyed that gene therapy can be
well tolerated prior to cystectomy.
In addition to the AdCD40L trial, our review identified
two other current studies in gene and vaccine therapy.
Celldex Therapeutics terminated a phase II trial of neoad-
juvant and adjuvant CDX-1307 with chemotherapy for
MIBC patients with Newly Diagnosed Muscle-Invasive
Bladder Cancer (The N-ABLE Trial). The study was ter-
minated due to poor accrual. CDX-1307 is a monoclonal
antibody targeting the mannose receptor and bHCG, a
common couplet in epithelial tumors [60]. CDX-1307 had
been studied previously in a phase I trial of multiple
tumors showing tolerability of the vaccine and increased
immune response [61]. The CDX-1307 phase II trial of-
fered a novel combination of vaccine therapy and chemo-
therapy, and such a treatment regimen can be emulated in
future studies. The trial’s failure to accrue its patient goal
may be a reflection of a current lack of faith in vaccine or
immune therapy for MIBC. Furthermore, Memorial
Sloan-Kettering Cancer Center and The National Cancer
Institute have completed a phase I vaccine trial of NY-
ESO-1, BCG, and sargramostim in patients who recently
underwent cystectomy for bladder cancer and express
NY-ESO-1 and/or LAGE-1 antigens histologically. NY-
ESO-1 and LAGE-1 are antigens expressed by testicular
germ cells and a limited number of tumors; however, pre-
vious results indicate that almost 50% of high grade
urothelial carcinomas express one or both of these anti-
gens, and thus, a vaccine for either may prove beneficial in
bladder cancer [62]. Previously, Sharma et al. have demon-
strated tolerable uptake of the vaccine with BCG and
granulocyte macrophage colony-stimulating factor for 6
patients that underwent cystectomy for MIBC [63].
NY-ESO-1 specific antibody responses were found in 5/6
patients with CD4 T-cell responses being found in 6/6
patients [63]. The new phase I study that has been com-
pleted had a project accrual of 24–28 patients and will
shed more light on the tolerability of the vaccine for
MIBC patients. The NY-ESO-1 vaccine has been used
tested previously in 16 patients with non-small cell lung
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oma and was well-tolerated [64]. The clinical outcomes
were mixed but it was noted that regulatory T cells in the
blood may limit the antibodies produced by the vaccine
and suppressing this immune response can possibly im-
prove the vaccine’s effectiveness [63]. This is one of the
shortcomings of the vaccine that requires further study.
Nonetheless, identifying eligible patients for the NY-ESO-
1 vaccine based on tumor specific antigens is a reflection
of MIBC research moving towards personalized medicine.
The safety profile of gene and vaccine therapy has yet
to be elucidated for any specific treatment. AdCD40L is
a promising immune-stimulating agent, but a future
phase II trial is necessary to further assess tolerability.
CDX-1307 theoretically would have benefit in bHCG
expressing bladder cancers; however, no bladder cancer
specific trial has been completed thus far. Lastly, NY-
ESO-1 and LAGE-1 offer targets for peptide vaccine
therapy, but results from the current NY-ESO-1 vaccine
trial and future clinical studies are required to assess the
tolerability and efficacy of the treatment.Expanding areas for future clinical trials
The Cancer Genome Atlas (TCGA) Research Network is a
widespread effort developed by the National Cancer Insti-
tute to collect specimens of several cancers with the hopes
of analyzing the genetics and molecular biology of tumors
to identify common mutations and targets for treatment
[65]. Recently, TCGA published data on 131 MIBC speci-
mens [66]. Mutations in 32 genes were found to be statisti-
cally significant, reinforcing current targets for clinical
trials and suggesting new areas for therapeutic studies
[66]. Using the data from the consortium to identify need
for future study may prove beneficial towards constructing
new trials.Limitations of our systematic review
All searches were limited to the Clinical Trials Registry,
MEDLINE, and Google. Any abstract or current clinical
trial unregistered or unreported by the aforementioned
databases may have been overlooked unless specifically
known of through recent conferences. However, our
searches detailed an extensive review of multiple databases
for perioperative MIBC trials.
Phase I and II trials of perioperative chemotherapy were
not substantially discussed above because of the wide
array of literature on the topic currently. Phase III peri-
operative chemotherapy subset studies of previous larger
phase III trials were not substantially discussed because of
overlap with trials included in past meta-analyses. Only
non-subset phase III trials were evaluated in detail
because of their possible changes in clinical management
of perioperative MIBC in the near future. Similarly, phaseI trials of targeted therapy were not closely addressed in
comparison to phase II trials.
Conclusion
Although the perioperative management of MIBC has
been limited to platinum-based chemotherapy, several
novel treatments are being evaluated for tolerability and
efficacy. Phase III trials directly comparing chemotherapy
regimens are now being studied, which will hopefully
classify different regimens for specific patients. Targeted
therapy with monoclonal antibodies is the closest non-
chemotherapy treatment to being implemented, but no
phase III trial of targeted therapy has been conducted.
Further trials in all treatment modalities are required to
address the large need for improved perioperative options
in MIBC management.
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